Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Working Capital Changes: 2018-2024

Historic Other Working Capital Changes for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to -$2.0 million.

  • Fulcrum Therapeutics' Other Working Capital Changes rose 93.42% to -$44,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 528.90%. This contributed to the annual value of -$2.0 million for FY2024, which is 286.66% down from last year.
  • As of FY2024, Fulcrum Therapeutics' Other Working Capital Changes stood at -$2.0 million, which was down 286.66% from $1.1 million recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Other Working Capital Changes peaked at $7.9 million during FY2020, and registered a low of -$13.2 million during FY2021.
  • For the 3-year period, Fulcrum Therapeutics' Other Working Capital Changes averaged around -$1.6 million, with its median value being -$2.0 million (2024).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first soared by 128.38% in 2023, then slumped by 286.66% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Other Working Capital Changes (Yearly) stood at $7.9 million in 2020, then tumbled by 267.11% to -$13.2 million in 2021, then spiked by 71.32% to -$3.8 million in 2022, then surged by 128.38% to $1.1 million in 2023, then slumped by 286.66% to -$2.0 million in 2024.